Xenon Pharmaceuticals Inc. (NASDAQ:XENE)‘s sales surged -36.56% in the recent quarter to 16,000%, yielding EPS of $(0.43).
The firm generated $(6.46M) in net cash from operations in the previous quarter, bringing its balance at the close of the quarter to 20.16M%. Net change in cash balance from the preceding period was $3.07M.
Let us look into the charts of the stock:
The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
With that, Xenon Pharmaceuticals Inc. reported $60.79M in total assets at the close of the quarter.
In the existing quarter, analysts are predicting EPS of $-0.39 from Xenon Pharmaceuticals Inc.. That compares with EPS of $(0.43) in the last quarter.
Coming to earnings, the firm recorded EPS of $-1.68 in the last financial year, while EPS for the current year is anticipated to grow -34.60% over the prior year.
EPS metric is impacted by profits a firm generates in a certain period and the number of due shares in it has in that given period. For the previous quarter where EPS was EPS $(0.43), shares outstanding were 17.97M. In that quarter, Xenon Pharmaceuticals Inc. incurred $- in cost of sales, resulting in gross profit of $- from the sales of 16,000% it generated in the quarter.
Who owns Xenon Pharmaceuticals Inc.? first, of the firm?s outstanding shares, 15.33M are free float. The firm?s shares sold short are 1.47%, implying a short ratio of 1.50.
As for the title, insiders own 1.80% of the firm, with that ownership moderately being a result of 123.46% insider transactions in the previous couple of months. Institutional shareholder ownership in the stock is 64.60%, stemming from -3.27% institutional transactions in the last few months.
Wall Street analysts on the average have a call of Buy on the stock of Xenon Pharmaceuticals Inc..